Phase 1 study of CB-839, a first-in-class oral inhibitor of glutaminase, in combination with paclitaxel in patients with advanced triple negative breast cancer Meeting Abstract
| Authors: | Kalinsky, K.; Harding, J. J.; DeMichele, A.; Infante, J. R.; Gogineni, K.; Owonikoko, T. K.; Isakoff, S.; Iliopoulos, O.; Patel, M. R.; Munster, P.; Telli, M. L.; Jenkins, Y.; Fiji, G. P.; Whiting, S. H.; Meric-Bernstam, F. |
| Abstract Title: | Phase 1 study of CB-839, a first-in-class oral inhibitor of glutaminase, in combination with paclitaxel in patients with advanced triple negative breast cancer |
| Meeting Title: | 40th Annual San Antonio Breast Cancer Symposium (SABCS 2017) |
| Journal Title: | Cancer Research |
| Volume: | 78 |
| Issue: | 4 Suppl. |
| Meeting Dates: | 2017 Dec 5-9 |
| Meeting Location: | San Antonio, TX |
| ISSN: | 0008-5472 |
| Publisher: | American Association for Cancer Research |
| Date Published: | 2018-02-01 |
| Language: | English |
| ACCESSION: | WOS:000425489402243 |
| PROVIDER: | wos |
| DOI: | 10.1158/1538-7445.SABCS17-PD3-13 |
| Notes: | Meeting Abstract: PD3-13 -- Source: Wos |
